Q1 Earnings Forecast for Kamada Issued By HC Wainwright

Kamada Ltd. (NASDAQ:KMDA) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for Kamada in a research note issued to investors on Thursday, January 8th. HC Wainwright analyst A. Fein forecasts that the biotechnology company will earn $0.10 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada’s Q2 2026 earnings at $0.11 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.11 EPS, FY2029 earnings at $0.77 EPS and FY2030 earnings at $0.82 EPS.

Kamada (NASDAQ:KMDA) last issued its earnings results on Monday, November 10th. The biotechnology company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Kamada had a net margin of 11.70% and a return on equity of 7.89%. The firm had revenue of $47.01 million during the quarter, compared to analysts’ expectations of $154.21 million.

Several other brokerages have also commented on KMDA. Wall Street Zen upgraded shares of Kamada from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Benchmark reissued a “buy” rating on shares of Kamada in a report on Thursday. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $14.00.

Kamada Stock Performance

Shares of KMDA opened at $8.04 on Friday. The firm has a market cap of $462.38 million, a PE ratio of 22.33, a PEG ratio of 0.69 and a beta of 0.93. The firm’s 50 day moving average price is $7.04 and its 200 day moving average price is $7.14. Kamada has a twelve month low of $5.54 and a twelve month high of $9.15.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Essex Investment Management Co. LLC lifted its stake in shares of Kamada by 22.4% in the third quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock valued at $2,751,000 after buying an additional 72,602 shares during the period. Acadian Asset Management LLC raised its holdings in Kamada by 3.1% in the 2nd quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company’s stock valued at $2,053,000 after acquiring an additional 7,925 shares in the last quarter. ARK Investment Management LLC lifted its position in shares of Kamada by 1.2% in the 3rd quarter. ARK Investment Management LLC now owns 256,217 shares of the biotechnology company’s stock worth $1,779,000 after acquiring an additional 2,943 shares during the period. Huntleigh Advisors Inc. grew its holdings in shares of Kamada by 4.3% during the 3rd quarter. Huntleigh Advisors Inc. now owns 141,562 shares of the biotechnology company’s stock worth $982,000 after purchasing an additional 5,786 shares in the last quarter. Finally, Legato Capital Management LLC increased its position in shares of Kamada by 18.7% during the third quarter. Legato Capital Management LLC now owns 114,404 shares of the biotechnology company’s stock valued at $794,000 after purchasing an additional 18,009 shares during the period. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.